CombiMatrix Regains Compliance With Nasdaq Listing Requirement | GenomeWeb

NEW YORK (GenomeWeb) – CombiMatrix today announced it has regained compliance to continue listing its shares on the Nasdaq after raising the closing bid price of its common stock to at least $1 per share for 10 days, which it did from Feb. 1 to Feb. 12.

CombiMatrix was warned last December that it could face delisting from the Nasdaq for failing to meet the stock exchange's $1 minimum bid price. It was given 180 calendar days in which to regain compliance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.